Regional Sales Director - Genetic and Metabolic Disorders
About the job
- At least 10 years of biopharmaceutical sales experience in Japan.
- Direct people management experience or indirect/peer leadership experience.
- A proven track record of consistently achieving sales targets.
- Experience launching rare disease and/or specialty products in the field.
- Highly developed people management and practical coaching skills.
- Ability to collaborate broadly and cross-functionally.
- Action orientation, learning agility, and a growth mindset.
- Comfort with change and ambiguity.
- Strong engagement, communication, and relational skills.
- Passion for making a positive contribution to the rare disease community.
- A bachelor's degree in science or another relevant area.
- Be accountable for overall sales performance of the assigned region and ensure each member of the region consistently delivers on their territory sales target.
- Set clear direction, guidance, and expectations for the region; prioritize key issues to direct organizational focus and resources; set the tone for the region; lead the team's day-to-day operation; and cultivate a driven and collaborative team culture.
- Lead development of a regional plan supporting national sales objectives; oversee translation of regional priorities into specific territory plans of action by MCCs; and ensure plans reflect area dynamics, customer insights, and business unit strategy.
- Drive disciplined field execution with urgency; monitor performance indicators and take necessary measures to deliver business objectives; and represent Alexion responsibly with external stakeholders as regional sales team leader.
- Provide ongoing, practical coaching for direct reports through regular field visits, one-on-one sessions, and business reviews; elevate team members' mindset, productivity, and capabilities; and support their long-term growth and development.
- Prior sales and/or sales management experience in rare disease.
- Broader commercial experience beyond sales, such as marketing, sales planning, KOL management, and/or other relevant commercial functions.
About the company
Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1992
Get referred to Alexion
See people who can refer or advise you
Simplify's Take
What believers are saying
- AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
- Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
- Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.
What critics are saying
- EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
- Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
- Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.
What makes Alexion unique
- Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
- Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
- AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Stock Options
Company Equity
401(k) Retirement Plan
Mental Health Support
Wellness Program
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Professional Development Budget
Conference Attendance Budget
Training Programs
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Relocation Assistance
Employee Referral Bonus
Meal Benefits
Commuter Benefits
Legal Services
Employee Discounts
Company Social Events
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
2%"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."
Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM. Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM
WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”
WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2
Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease. . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old